Abstract: Provided is a method and system for building a compliance software service using reusable and configurable components. In one example, the method may include receiving a request to build a software in association with an identified jurisdiction from among a plurality of jurisdictions, retrieving a plurality of configurable software components which comprise built-in functionality that is generic across the plurality of jurisdictions, dynamically configuring non-generic functionality for the identified jurisdiction within the plurality of configurable software components based on inputs received from a user, and creating a software program for the identified jurisdiction based on the dynamically configured software components and storing a file including the created software program in a storage device.

Abstract: Provided is a method and system for building a compliance software service using reusable and configurable components. In one example, the method may include receiving a request to build a software in association with an identified jurisdiction from among a plurality of jurisdictions, retrieving a plurality of configurable software components which comprise built-in functionality that is generic across the plurality of jurisdictions, dynamically configuring non-generic functionality for the identified jurisdiction within the plurality of configurable software components based on inputs received from a user, and creating a software program for the identified jurisdiction based on the dynamically configured software components and storing a file including the created software program in a storage device.

Abstract: A method and system for building a compliance software service using reusable and configurable components. The method may include one or more of receiving a request to build a software in association with an identified jurisdiction from among a plurality of jurisdictions, retrieving a plurality of configurable software components which comprise built-in functionality that is generic across the plurality of jurisdictions, dynamically configuring non-generic functionality for the identified jurisdiction within the plurality of configurable software components based on inputs received from a user, and creating a software program for the identified jurisdiction based on the dynamically configured software components and storing a file including the created software program in a storage device.

Abstract: Provided is a method and system for building a compliance software service using reusable and configurable components. In one example, the method may include receiving a request to build a software in association with an identified jurisdiction from among a plurality of jurisdictions, retrieving a plurality of configurable software components which comprise built-in functionality that is generic across the plurality of jurisdictions, dynamically configuring non-generic functionality for the identified jurisdiction within the plurality of configurable software components based on inputs received from a user, and creating a software program for the identified jurisdiction based on the dynamically configured software components and storing a file including the created software program in a storage device.

Abstract: The lyophilized solid pharmaceutical compositions comprising a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof are disclosed.

Abstract: Pharmaceutical compositions comprising cefepime or a pharmaceutically acceptable salt thereof, tazobactam or a pharmaceutically acceptable salt thereof, and arginine or a pharmaceutically acceptable salt thereof; and their use in treatment, control or prevention of bacterial infection is disclosed.

Abstract: The lyophilized solid pharmaceutical compositions comprising a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof are disclosed.

Abstract: The present invention relates to an extract of Cissampelos pareira, its pharmaceutical compositions, and its therapeutic use in the prevention and treatment of dengue. It also relates to processes for the preparation of these extracts.

Abstract: The present invention relates to pharmaceutical compositions of tamsulosin or salts thereof. In particular, the invention relates to pharmaceutical compositions comprising a core of tamsulosin or salts, hydrates thereof and at least one specialized coating over the core. Such compositions of tamsulosin may exhibit desired release kinetics with excellent storage stability and particularly, levels of degradants in the formulation during storage can be effectively controlled. The invention also includes a process of preparing such compositions and additionally combination with other pharmaceutical ingredient.

Abstract: There is provided a single unit oral dose pharmaceutical composition comprising a) levodopa or salts thereof from about 50 mg to about 300 mg in extended release form, b) carbidopa or salts thereof from about 10 mg to about 100 mg in extended release and c) entacapone or salts thereof from about 100 mg to about 1000 mg in immediate release form, optionally with other pharmaceutically acceptable excipients. The invention also relates to process of preparation of such compositions.

Abstract: The invention relates to crystalline barium salt of (S)-omeprazole, which is (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole. The invention also relates to processes for preparing crystalline barium salt of (S)-omeprazole and pharmaceutical compositions that include the crystalline barium salt of (S)-omeprazole so prepared.

Abstract: The invention relates to crystalline barium salt of (S)-omeprazole, which is (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole. The invention also relates to processes for preparing crystalline barium salt of (S)-omeprazole and pharmaceutical compositions that include the crystalline barium salt of (S)-omeprazole so prepared.

Abstract: There is provided a single unit oral dose pharmaceutical composition comprising a) levodopa or salts thereof from about 50 mg to about 300 mg in extended release form, b) carbidopa or salts thereof from about 10 mg to about 100 mg in extended release and c) entacapone or salts thereof from about 100 mg to about 1000 mg in immediate release form, optionally with other pharmaceutically acceptable excipients. The invention also relates to process of preparation of such compositions.

Abstract: The invention relates to processes for the preparation of substantially pure ziprasidone. The invention also relates to the preparation of acid addition salts of ziprasidone. More particularly, it relates to the preparation of substantially pure hydrochloride salt of ziprasidone. The invention also relates to pharmaceutical compositions that include the substantially pure ziprasidone or ziprasidone hydrochloride and use of said compositions for treating schizophrenia.

Abstract: There is provided a single unit oral dose pharmaceutical composition comprising a) levodopa or salts thereof from about 50 mg to about 300 mg in extended release form, b) carbidopa or salts thereof from about 10 mg to about 100 mg in extended release and c) entacapone or salts thereof from about 100 mg to about 1000 mg in immediate release form, optionally with other pharmaceutically acceptable excipients. The invention also relates to process of preparation of such compositions.

Abstract: The invention relates to processes for the preparation of substantially pure ziprasidone. The invention also relates to the preparation of acid addition salts of ziprasidone. More particularly, it relates to the preparation of substantially pure hydrochloride salt of ziprasidone. The invention also relates to pharmaceutical compositions that include the substantially pure ziprasidone or ziprasidone hydrochloride and use of said compositions for treating schizophrenia.

Abstract: A process for the production of amorphous atorvastatin calcium and stabilized, amorphous atorvastatin calcium is provided.

Abstract: The present invention relates to substituted pyrrole derivatives, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and methods of treating cholesterol-related diseases and related symptoms.

Abstract: The present invention relates to substituted pyrrole derivatives, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and methods of treating cholesterol-related diseases and related symptoms.

Abstract: The invention relates to processes for the preparation of clopidogrel and salts thereof. The inventors have developed a process for preparing racemic clopidogrel by racemizing R(?) clopidogrel. The process includes the step of reacting R(?) clopidogrel with a powered anhydrous base in one or more solvents.